EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Distributional Cost-Effectiveness Analysis of Blood-Based Noninvasive Screening for MASLD among US Veterans: Assessing Health Equity Impact in the Era of Emerging Therapies

Wanyi Chen, Stephanie T. Chang, Ramsey C. Cheung, Donald B. Chalfin, Kinpritma Sangha, Szu-Yu Zoe Kao, Artem T. Boltyenkov

PharmacoEconomics · 20.11.2026

DOI: 10.1007/s40273-026-01677-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PharmacoEconomics, online erschienen am 20.11.2026. Verfasst von Wanyi Chen und 6 weiteren Autor:innen. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Siemens Healthineers.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • Siemens Healthineers

Zitieren

APA

Chen, W., Chang, S. T., Cheung, R. C., Chalfin, D. B., Sangha, K., Kao, S. Z., & Boltyenkov, A. T. (2026). Distributional Cost-Effectiveness Analysis of Blood-Based Noninvasive Screening for MASLD among US Veterans: Assessing Health Equity Impact in the Era of Emerging Therapies. PharmacoEconomics. https://doi.org/10.1007/s40273-026-01677-2

Vancouver

Chen W, Chang ST, Cheung RC, Chalfin DB, Sangha K, Kao SZ, et al. Distributional Cost-Effectiveness Analysis of Blood-Based Noninvasive Screening for MASLD among US Veterans: Assessing Health Equity Impact in the Era of Emerging Therapies. PharmacoEconomics. 2026. doi:10.1007/s40273-026-01677-2

BibTeX
@article{Chen2026,
  author = {Chen, Wanyi and Chang, Stephanie T. and Cheung, Ramsey C. and Chalfin, Donald B. and Sangha, Kinpritma and Kao, Szu-Yu Zoe and Boltyenkov, Artem T.},
  title = {Distributional Cost-Effectiveness Analysis of Blood-Based Noninvasive Screening for MASLD among US Veterans: Assessing Health Equity Impact in the Era of Emerging Therapies},
  journal = {PharmacoEconomics},
  year = {2026},
  doi = {10.1007/s40273-026-01677-2}
}
Kostenlos starten →